LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

510.73 0.17

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

495.54

Max

522.23

Belangrijke statistieken
By Trading Economics
Inkomsten	-36M -94M
Verkoop	-9.7M 311M
EPS	-1.38
Winstmarge	-30.318
Werknemers	915
EBITDA	-43M -93M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+31.74% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	156M 12B
Vorige openingsprijs	510.56
Vorige sluitingsprijs	510.73

Nieuwssentiment

By Acuity

36%

64%

104 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 mei 2026, 20:36 UTC

Acquisities, Fusies, Overnames

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mei 2026, 23:34 UTC

Marktinformatie

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mei 2026, 23:28 UTC

Marktinformatie

Winsten

Global Forex and Fixed Income Roundup: Market Talk

19 mei 2026, 23:28 UTC

Marktinformatie

Winsten

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mei 2026, 23:10 UTC

Marktinformatie

Global Equities Roundup: Market Talk

19 mei 2026, 23:10 UTC

Marktinformatie

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mei 2026, 22:02 UTC

Winsten

ZTO Express (Cayman): Di Xu to Resign From Board

19 mei 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mei 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mei 2026, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mei 2026, 21:37 UTC

Winsten

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mei 2026, 21:31 UTC

Acquisities, Fusies, Overnames

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mei 2026, 21:01 UTC

Winsten

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mei 2026, 20:58 UTC

Winsten

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mei 2026, 20:46 UTC

Populaire aandelen

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mei 2026, 20:43 UTC

Marktinformatie

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mei 2026, 20:34 UTC

Winsten

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries 4Q EPS 5c >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries 4Q Sales $1.4B >JHX

19 mei 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mei 2026, 20:18 UTC

Marktinformatie

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mei 2026, 20:13 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

19 mei 2026, 20:13 UTC

Marktinformatie

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mei 2026, 20:03 UTC

Acquisities, Fusies, Overnames

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mei 2026, 20:03 UTC

Acquisities, Fusies, Overnames

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mei 2026, 20:02 UTC

Acquisities, Fusies, Overnames

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mei 2026, 20:02 UTC

Acquisities, Fusies, Overnames

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mei 2026, 19:23 UTC

Marktinformatie

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

31.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 674.25 USD 31.74%

Hoogste 964 USD

Laagste 550 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

104 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.